To understand the role of the eosinophilopoietic cytokine IL-5 in humans, the posttreatment eosinophilic response in a group of microfilaria (mf)-positive patients with onchocerciasis (n = 10) was examined before and after treatment with diethylcarbamazine (6 mg/kg for 7 d). Sequential blood samples were assessed at 24 and 1 h before treatment (baseline values), then at frequent intervals over the next 14 d. Symptom scores, skin microfilariae (mf), and peripheral blood eosinophil counts were recorded as a function of time after treatment, and serum levels of IL-5 were quantitated by a highly sensitive (sensitivity > 20 pg/ml) monoclonal-based ELISA. Pretreatment eosinophil counts ranged from 240 to 1,186 eosinophils/pi (geometric mean, 675), and the mf counts from 10 to 218 per mg skin (geometric mean, 79). After an initial decline in the peripheral eosinophil count to 28±8% of pretreatment levels at 8 h after beginning treatment, the eosinophil counts steadily increased over the next 2 wk, reaching a maximum at 14 d (257±38% of pretreatment levels). Serum levels of IL-5 rose sharply from pretreatment levels to a peak of 70.5±11 pg/ml by 24 h after treatment. Serum IL-5 remained elevated over the next 2-3 d and declined toward baseline by -6 d after treatment, at which time the eosinophil levels were steadily increasing. IL-3 and granulocyte macrophage colony-stimulating factor, two other cytokines implicated in eosinophilopoeisis, were not detectable in the serum at any time before or after treatment. The rise in serum IL-5 before the posttreatment eosinophilia seen in this group of patients with onchocerciasis demonstrates a temporal relationship between IL-5 and the subsequent development of eosinophilia and implicates IL-5 as an important mediator of eosinophilia in humans. (J. Clin.
Introduction
Blood and tissue eosinophilia is a characteristic response to infection with a variety of helminth parasites. Recently, IL-5 has been implicated in mediating this response in vitro both in A. P. Limaye is a recipient of a Howard Hughes Medical Institute/National Institutes of Health Research Scholarship.
bone marrow cultures (1) and in cross-sectional studies ofeosinophilic individuals (2) . Although other cytokines, particularly IL-3 and granulocyte macrophage colony-stimulating factor (GM-CSF),1 have been shown to stimulate eosinophilopoeisis directly in vitro and to induce eosinophilia in vivo (3), only IL-5 appears to be eosinophil (and probably basophil) specific in its colony-stimulating activity (4, 5) . The role of IL-5, however, has not been examined prospectively in a physiologic in vivo eosinophilic response in humans.
Treatment of many helminth infections-including lymphatic filariasis (6) , schistosomiasis (6) , and onchocerciasis (7, 8) -has consistently been shown to cause a characteristic rise in peripheral blood eosinophil levels, the magnitude ofwhich is felt to relate to the parasite burden (6, 8) . Therefore, because this eosinophilia is such a predictable sequela of the treatment of onchocerciasis, the relationship of IL-5 to the induction of this response could be directly assessed in Onchocerca-infected individuals.
Methods
Study population. 10 male patients from Tamale, Ghana, aged 18-51 yr with proven onchocerciasis, were selected for study (Table I) . Identification and quantification of 0. volvulus microfilariae, recovered from skin snips of scapulae, iliac crests, thighs, and calves using a Walzertype corneoscleral punch, established the diagnosis and intensity of infection as previously described (7) . The intensities ofinfection ranged from 10 to 218 mf/mg of skin. Two individuals without evidence of onchocerciasis (endemic normal individuals) were also studied. These individuals were from the same region of Ghana and were clinically and parasitologically free of onchocercal infection. Stool microscopic examination for other parasites was performed at the initiation of the study (Table I) .
Treatment protocol. Patients and controls received 200 mg ofdiethylcarbamazine (DEC) orally once a day for 7 d, as previously described (6) . The study was performed at a time (1982) Assay for quantitation of serum IL-5, IL-3, and GM-CSF. Cytokines were quantified in patient sera by immunoenzymetric assays described previously (2) . "U"-bottom polyvinylchloride microtiter plates were coated with a 100 Ml/well volume ofthe appropriate capture antibody (see below) diluted in PBS for 2 h at 370C. The plates were washed three times with 0.15 M NaCl plus 0.05% Tween 20 using a Microwash II (Skatron Inc., Sterling, VA) automatic plate washer. The samples were incubated for 2 h at room temperature. After washing, the appropriate nitroiodophenyl (NIP)-derivatized detecting MAb (see below) was added in 0.01 M PBS plus 1 mg/ml BSA plus 0.05% Tween 20 (PBS-BSA-Tween) and incubated for 1 h at room temperature. After washing, bound NIP-MAb was detected by incubating a monoclonal anti-NIP (J4) immunoperoxidase conjugate (800 ng/ml) in PBS-BSATween for 1 h at room temperature. Finally, after washing, the plates were developed using of the peroxidase chromogenic substrate 2-2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma Chemical Co., St. Louis, MO) (1 mg/ml) in the presence of H202. Plates were read using a microtiter plate reader (Molecular Devices, Menlo Park, CA). Unknown values were interpolated from standard curves prepared using purified recombinant standards graciously provided by Schering Research (Bloomfield, NJ). The following antibody pairs (coating antibody and NIP [hapten]-derivatized detecting antibody, respectively) and recombinant standards were used in the cytokine immunoenzymetric assays carried out in this study: for IL-5, JESI-39D10 (10 ;sg/ml) and JESl-5A10-NIP (1 yg/ml) with L cell-derived recombinant standard; for IL-3, BVD8-3G1 1 (1 ;&g/ml) and BVD3-IF9-NIP (1 ttg/ml) with yeast-derived standard; and for GM-CSF, BVD2-23B6 (10 ;g/ml) and BCD2-21C 1I-NIP (1 ug/ml) with E. coli-derived recombinant standard.
Data analysis. Unless otherwise stated, data are expressed as geometric means. Correlations were assessed by Spearman rank.
Results
Pretreatment assessment. Pretreatment blood eosinophil counts and serum IL-S levels were determined as the means of the two pretreatment observations for each of the 10 patients with onchocerciasis and the two endemic normal individuals (Table I) . Although there was a broad range of eosinophilia (240-1,186/4d) among the patients with onchocerciasis, these pretreatment levels were significantly elevated (P < 0.05) when compared to the endemic uninfected individuals or normal North American blood donors (data not shown). Interestingly, the pretreatment eosinophil levels were positively correlated with the levels of skin microfilariae (P < 0.007).
Serum levels of IL-5 pretreatment were below the limits of detectability (< 20 pg/ml) in five ofthe 10 patients; in the other four, there were measurable levels of serum IL-5 (range, 25-159 pg/ml). There was, however, no relationship between the pretreatment levels of serum IL-5 and the pretreatment levels of blood eosinophils or skin microfilariae.
Effects of microfilaricidal treatment on blood eosinophils and serum IL-S levels. Data for two representative individuals, one with microfiladermia and one uninfected endemic control, are illustrated in Fig. 1 . When DEC was given to the patient with onchocerciasis, blood eosinophil levels dropped within 1-3 h ofthe first dose and reached their nadir at -8-12 h (Fig.  1 A) . After this transient eosinopenia, the eosinophil levels rose to pretreatment values by 72-96 h and peaked at 6 d. In contrast, blood eosinophil levels in the endemic normal individual did not vary significantly after receiving the same dose ofDEC (Fig. 1 A) . Serum IL-5 levels were assessed in parallel (Fig. 1 B) .
In the patient with onchocerciasis, serum IL-5 remained at baseline for 8 h and then rose to a peak at 24 h. Soon thereafter, the serum IL-5 levels diminished, returning to pretreatment levels by 72 h. As expected, the uninfected individual showed no change in serum IL-5 levels over the 2-wk period ofobservations ( Fig. 1 B) . Interleukin-S-mediated Onchocercal Eosinophilia 1419 5( Similar findings were seen in all 10 of the treated patients with onchocerciasis (Fig. 2) . After initial declines in the peripheral eosinophil counts to 28.5±8% ofpretreatment levels at 8 h after treatment, the eosinophil counts steadily increased over the next 2 wk, reaching a maximum at 14 d (257±38% of pretreatment levels). Serum levels of IL-5 rose sharply from pretreatment levels by 8-12 h, reaching a peak (over baseline) of 70. There was no relationship, however, between the levels of IL-5 and the levels ofeosinophilia seen posttreatment, nor was there a correlation between the patients' skin microfilariae and IL-5 levels.
In none ofthe serum samples tested was there any measurable GM-CSF or IL-3 (data not shown).
Discussion
Parasitic helminth infections, along with atopic diseases, are the conditions most commonly associated with tissue and peripheral blood eosinophilia. In rodents infected with either Nippostrongylus braziliensis (9) or Schistosoma mansoni (10), this parasite-induced tissue and peripheral blood eosinophilia has been shown to be mediated by IL-5. In humans, the role of IL-5 has been, until recently, limited to in vitro studies. In these in vitro studies, human IL-5 has been clearly shown to be a potent stimulus for eosinophil growth and differentiation (1) . In contrast to IL-3 and GM-CSF (the other cytokines implicated in mediating eosinophilia), IL-5 has also been shown to be induced at high levels (mRNA and protein) in lymphocytes of eosinophilic patients with filarial infections (2) , an observation suggesting a critical role for this lymphokine in parasite-induced eosinophilia. The present study extends these earlier in vitro findings to the in vivo situation and, in so doing, demonstrates the role of IL-5 as a critical mediator of the posttreatment eosinophilia seen in human onchocerciasis.
Eosinophilia has been commonly reported after treatment of infections with S. mansoni (6) and most of the filariae including W bancrofti (6), B. malayi, 0. volvulus (7, 8) , Loa loa (unpublished), and M. ozzardi (1 1). Previously, it had been shown that magnitude ofthe posttreatment eosinophilia in W. bancrofti infections was a direct function of the pretreatment parasite burden (i.e., numbers of blood microfilariae), an observation suggesting that the magnitude of the eosinophil response depends on the degree ofantigenic stimulation induced by the parasites cleared from the blood (6) . In the present study, however, it was the pretreatment levels ofeosinophils that were positively associated with skin microfilarial densities.
The most important issue raised by the present study concerns the kinetics ofIL-5 appearance and its temporal relationship to the rise in blood eosinophils. The fact that the eosino- philic response took several days to develop and 7-14 d to peak suggests that the increase in circulating eosinophils reflected active bone marrow eosinophilopoeisis rather than compartmental shifts. In addition, the relatively constant relationship between the time to the peak ofserum IL-5 and the time to the peak eosinophilia is consistent with IL-5's action on eosinophilic progenitors in the bone marrow, a hypothesis already suggested after the administration ofanti-IL-5 antibody to helminth-infected rodents (12) . The role of IL-5 in eosinophilic conditions not caused by parasites remains unclear, although observations on the idiopathic hypereosinophilic syndrome (13) and on the eosinophilia-myalgia syndrome (14) have implicated IL-5 as an important mediator. Additionally, T cells from patients with reactive eosinophilia have been shown to produce IL-5 upon IL-2 stimulation in vitro (15) ; and in eosinophilic patients undergoing IL-2/LAK cell tumor immunotherapy, serum IL-5 has been found to be elevated, with kinetics of appearance of peak eosinophilia analogous to that observed in the present study (16) . That IL-5 (and not GM-CSF or IL-3) was mediating this response was demonstrated by the complete absence of either of these in any of the serum samples tested.
The present findings, while clearly implicating IL-5 as the major mediator of the post-treatment eosinophilia seen in onchocerciasis, do not specifically address the nature ofthe stimulus required for the induction of this eosinophilopoeitic cytokine. There are hypotheses suggesting that either particular structural motifs found in parasite antigens are "eosinophilo- 1420 Limaye et al. I1 genic" or that the chronic antigenic stimulation found in helminth infections plays the major role in inducing eosinophilia. By whatever mechanism, the present findings clearly demonstrate that acute stimulation ofthe immune system by parasite antigens (as seen with treatment of filarial infections) overcomes the regulatory mechanisms that keep IL-5 production in check. With the induction of IL-5 comes the predictable rise in peripheral blood eosinophilia seen after treatment ofonchocerciasis (and presumably, other helminth infections). This physiologic response to parasite antigen release should provide an excellent model for continued study ofthe in vivo regulation of eosinophilia, ofthe nature ofits determinants, and ofthe effector mechanisms underlying it.
